|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Pancreatic Cancer - Gemzar Dominance will Continue among High Levels of Persistent Unmet Needs
Datamonitor, March 2009, Pages: 89
Only 15-20% of pancreatic cancer patients have resectable disease, therefore most receive systemic therapy. Gemzar (gemcitabine; Eli Lilly) forms the current standard of care for advanced disease. Despite this, no treatment is truly effective, with five-year survival at 5% for all stages of disease. Significant unmet needs therefore remain, with ample commercial opportunities for drug developers.
Scope
- Pancreatic cancer overview, including definition, risk factors, epidemiology forecasts and discussion of unmet needs
- Current diagnosis and treatment of pancreatic cancer, including drug regimens used by stage and ongoing controversies
- Examination of the late-phase pancreatic cancer pipeline and market opportunities for drug developers
- Stakeholder opinions based on qualitative interviews with key opinion leaders in the field of pancreatic cancer
Highlights of this title
Gemzar is the current standard of care for unresectable locally advanced and metastatic pancreatic cancer. Despite this, Gemzar is only associated with median overall survival of 5.7 months and a one-year survival rate of 18%. It is therefore clear that treatment of pancreatic cancer continues to be plagued by high levels of unmet need.
Other lines of therapy in pancreatic cancer remain ill defined due to a lack of definitive randomized clinical trial data. Controversy persists regarding the use of neoadjuvant versus adjuvant therapy, while the role of radiotherapy alongside chemotherapy in these settings continues to provoke debate.
The pancreatic cancer pipeline is relatively active, with six Phase III agents. Despite this, Gemzar is set to retain its leading status for the foreseeable future. While promising Phase II results have been shown, this has yet to be translated into Phase III efficacy. As a result, no pipeline agent has yet shown the potential to replace Gemzar.
Key reasons to purchase this title
- Identify the limitations of current therapy available to pancreatic cancer patients and the potential of future therapy
- Understand current epidemiological trends in pancreatic cancer and ongoing treatment controversies
- Assess the opportunities for innovative targeted therapies in the pancreatic cancer market, particularly in metastatic disease
Customers who bought this item also bought
Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged
Strategic Perspectives: Pancreatic Cancer - Gemcitabine Combination Therapy is the Future
Cancer Pancreatic Cancer
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Pancreatic Cancer Therapy Area Pipeline Report
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
Stakeholder Opinions: Primary Brain Cancer
Niche Cancers 2001: Pancreatic Cancer
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Target Product Profiles 2008: Physician Insights on Key Attributes - Pancreatic Cancer (Advanced)
Cancer Drug Resistance
Pipeline Insight: Cancer Overview - Increasing Diversity Offers Both High Risk and Reward
|
|
|
|
